Integrating single-cell omics and ancestry-adjusted eQTL mapping to characterize Tuberculosis immune response
Project Number1R21AI183161-01
Contact PI/Project LeaderHENN, BRENNA M
Awardee OrganizationUNIVERSITY OF CALIFORNIA AT DAVIS
Description
Abstract Text
Tuberculosis (TB) remains the leading infectious cause of death worldwide. A quarter of the
human population is exposed to TB of which 5-15% will progress to active disease. Despite its
extreme prevalence, prediction of disease progression is poor. To address this, our proposal
integrates whole genome sequencing and single-cell RNA sequencing (scRNA-Seq) on the
entire repertoire peripheral blood mononuclear cells (PBMCs) at three crucial TB disease states:
latent TB infection, recent Mtb infection, and post-TB treatment completion. We will be the first
to leverage this unique study design across TB states, for expression quantitative trait
loci (eQTL) mapping. Our study population in South Africa resides in a TB-endemic area
where we have over a decade of established research infrastructure, enabling us to efficiently
capture these critical TB phenotypes at a relatively low cost. Previous TB eQTL mapping
studies have been limited by inadequate phenotyping (e.g., samples from TB cases months-
years after clearing infection), bulk RNA-seq (aggregating cell-type specific effects), or
scRNAseq on one cell type. We are generating CITE-seq profiles from PBMCs, a cutting-edge
technology that enables simultaneous profiling of gene expression and cell surface protein
composition at the single-cell level [funded by CZI, co-PI Suliman]. This approach allows us to
capture the fine-scale heterogeneity of immune cell states. To identify the genetic variants that
regulate these identified cellular and transcriptomic changes, we propose to generate whole
genome sequencing data paired with the transcriptomic data for eQTL fine-mapping. South
African populations exhibits high levels of genetic heterozygosity and are multiway admixed,
amplifying statistical power for discovering eQTL variants. To characterize the unique genetic
diversity of our population we have optimized state-of-the-art ancestry estimation methods.
Outcomes of this grant include multiomic data from 225 individuals across three TB
states and eQTL identification of ancestry- and cell-specific variants which affect gene
expression in early TB infection.
Public Health Relevance Statement
Project Narra�ve
This study integrates new approaches in single cell RNA-sequencing and genomics to gain
insight into the pathophysiology and immune response of tuberculosis (TB)—a WHO global
health emergency since 1993. This study will characterize the gene�c variants associated with
specific immune cell responses in latent TB controls and recently ac�vated TB cases,
contribu�ng immunogene�c profiles and datasets relevant in therapeu�c research and vaccine
development.
NIH Spending Category
No NIH Spending Category available.
Project Terms
Adaptive Immune SystemAddressAdmixtureAdultAffectAftercareAreaAsian ancestryBiological AssayCause of DeathCell AggregationCell Surface ProteinsCellsCellular Indexing of Transcriptomes and Epitopes by SequencingCentenarianCodeColorCommunicable DiseasesComplexDataData SetDiseaseDisease ProgressionEpidemiologyEuropeanEventExhibitsExposure toFunctional disorderFundingGene ExpressionGenesGeneticGenetic Predisposition to DiseaseGenetic VariationGenomicsGenotypeGrantHeterogeneityHeterozygoteHumanImmuneImmune responseImmunogeneticsImmunologicsIn VitroIncidenceIndividualInfectionInnate Immune SystemInterferon Type IILinkage DisequilibriumMapsMeasuresMedicalMethodsModelingMultiomic DataMycobacterium tuberculosisNon-Insulin-Dependent Diabetes MellitusOutcomeParticipantPeripheral Blood Mononuclear CellPhenotypePopulationPopulation HeterogeneityPrevalenceProcessQuantitative Trait LociResearchResearch DesignResearch InfrastructureSamplingSouth AfricaSouth AfricanSouth AsianTechnologyTuberculosisUntranslated RNAVaccinesVariantWorkcell typeco-infectioncostdifferential expressionfollow-upgenetic architecturegenetic variantgenome sequencingglobal health emergencyimprovedinsightmultimodalitynovelnovel strategiespathogen exposureprotein expressionrecruitresearch and developmentresponsesingle-cell RNA sequencingsoutheast Asianstudy populationtranscriptome sequencingtranscriptomicstuberculosis treatmentvaccine developmentwhole genome
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
047120084
UEI
TX2DAGQPENZ5
Project Start Date
01-August-2024
Project End Date
30-June-2026
Budget Start Date
01-August-2024
Budget End Date
30-June-2025
Project Funding Information for 2024
Total Funding
$272,202
Direct Costs
$193,542
Indirect Costs
$78,660
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$272,202
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R21AI183161-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R21AI183161-01
Patents
No Patents information available for 1R21AI183161-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R21AI183161-01
Clinical Studies
No Clinical Studies information available for 1R21AI183161-01
News and More
Related News Releases
No news release information available for 1R21AI183161-01
History
No Historical information available for 1R21AI183161-01
Similar Projects
No Similar Projects information available for 1R21AI183161-01